These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 15899800)

  • 1. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
    Martens JW; Nimmrich I; Koenig T; Look MP; Harbeck N; Model F; Kluth A; Bolt-de Vries J; Sieuwerts AM; Portengen H; Meijer-Van Gelder ME; Piepenbrock C; Olek A; Höfler H; Kiechle M; Klijn JG; Schmitt M; Maier S; Foekens JA
    Cancer Res; 2005 May; 65(10):4101-17. PubMed ID: 15899800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
    Maier S; Nimmrich I; Koenig T; Eppenberger-Castori S; Bohlmann I; Paradiso A; Spyratos F; Thomssen C; Mueller V; Nährig J; Schittulli F; Kates R; Lesche R; Schwope I; Kluth A; Marx A; Martens JW; Foekens JA; Schmitt M; Harbeck N;
    Eur J Cancer; 2007 Jul; 43(11):1679-86. PubMed ID: 17601725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
    Sieuwerts AM; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; Portengen H; Klijn JG; Foekens JA
    Clin Cancer Res; 2005 Oct; 11(20):7311-21. PubMed ID: 16243802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
    Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
    J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
    Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.
    van Agthoven T; Sieuwerts AM; Meijer-van Gelder ME; Look MP; Smid M; Veldscholte J; Sleijfer S; Foekens JA; Dorssers LC
    J Clin Oncol; 2009 Feb; 27(4):542-9. PubMed ID: 19075277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
    Foekens JA; Romain S; Look MP; Martin PM; Klijn JG
    Cancer Res; 2001 Feb; 61(4):1421-5. PubMed ID: 11245445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
    Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
    Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
    Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
    Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients.
    Altundag O; Altundag K; Gunduz M
    Med Hypotheses; 2004; 63(4):684-7. PubMed ID: 15325017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
    Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
    Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.
    Rokavec M; Schroth W; Amaral SM; Fritz P; Antoniadou L; Glavac D; Simon W; Schwab M; Eichelbaum M; Brauch H
    Cancer Res; 2008 Dec; 68(23):9799-808. PubMed ID: 19047159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant methylation of the THRB gene in tissue and plasma of breast cancer patients.
    Ling Y; Xu X; Hao J; Ling X; Du X; Liu X; Zhao X
    Cancer Genet Cytogenet; 2010 Jan; 196(2):140-5. PubMed ID: 20082849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma.
    Manders P; Beex LV; Tjan-Heijnen VC; Span PN; Sweep CG
    Cancer; 2003 Nov; 98(10):2125-32. PubMed ID: 14601081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.
    Jansen MP; Sieuwerts AM; Look MP; Ritstier K; Meijer-van Gelder ME; van Staveren IL; Klijn JG; Foekens JA; Berns EM
    J Clin Oncol; 2007 Feb; 25(6):662-8. PubMed ID: 17308270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response.
    Helleman J; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; Meijer-van Gelder ME; Sieuwerts AM; Klijn JG; Sleijfer S; Foekens JA; Berns EM
    Clin Cancer Res; 2008 Sep; 14(17):5555-64. PubMed ID: 18765548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
    Bostner J; Ahnström Waltersson M; Fornander T; Skoog L; Nordenskjöld B; Stål O
    Oncogene; 2007 Oct; 26(49):6997-7005. PubMed ID: 17486065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing of LRRC49 and THAP10 genes by bidirectional promoter hypermethylation is a frequent event in breast cancer.
    De Souza Santos E; De Bessa SA; Netto MM; Nagai MA
    Int J Oncol; 2008 Jul; 33(1):25-31. PubMed ID: 18575747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.